Inclusion body myositis and Alzheimer's disease are age-related disorders characterized in part by the appearance of intracellular lesions composed of filamentous aggregates of the microtubule-associated protein tau. Abnormal tau phosphorylation accompanies tau aggregation and may be an upstream pathological event in both diseases. Enzymes implicated in tau hyperphosphorylation in Alzheimer's disease include members of the casein kinase 1 family of phosphotransferases, a group of structurally related protein kinases that frequently function in tandem with the ubiquitin modification system. To determine whether casein kinase 1 isoforms associate with degenerating muscle fibers of inclusion body myositis, muscle biopsy sections isolated from sporadic disease cases were subjected to double-label fluorescence immunohistochemistry using selective anti-casein kinase 1 and anti-phospho-tau antibodies. Results showed that the alpha isoform of casein kinase 1, but not the delta or epsilon isoforms, stained degenerating muscle fibers in all eight inclusion body myositis cases examined. Staining was almost exclusively localized to phospho-tau-bearing inclusions. These findings, which extend the molecular similarities between inclusion body myositis muscle and Alzheimer's disease brain, implicate casein kinase 1 alpha as one of the phosphotransferases potentially involved in tau hyperphosphorylation.

Migraine is a common, episodic neurological disorder that includes headache, nausea and hypersensitivity to sensory stimuli. During the headache phase of migraine, migraine patients can be especially hypersensitive to thermal stimuli. The unpredictable and episodic nature of migraine makes it difficult to treat and much of the mechanism of migraine has yet to be elucidated. A T44A substitution in casein kinase 1δ is inherited with migraine with aura. A transgenic mouse model suggests that animals with this mutation exhibit increased sensitivity to thermal stimuli after injection with nitroglycerin (NTG). We performed behavior assays that measure animal responses to thermal stimuli, after injection with NTG, a known migraine-inducer in human migraine patients. Female animals with the CK1δ-T44A mutation are more sensitive than wildtype littermates, suggesting a sex difference emerges in pain sensitivity in animals that express the CK1δ-T44A but not in wildtype siblings. Female CK1δ-T44A animals are more sensitive to the effects of NTG on pain than male CK1δ-T44A mice. This indicates a potential sex hormone related pain response. Since estrogen is implicated in both migraine and pain response, we test the thermal sensitivity of heterozygous ERβKO/+ and CK1δ-T44A; ERβKO/+ mice compared to wildtype and CK1δ-T44A mice. Overall thermal sensitivity is decreased before stress of injection in both male and female ERβKO/+ and CK1δ-T44A: ERβKO/+ mice. This demonstrates that ERβ is necessary for thermal nociception in untreated mice. However, after injection with saline or NTG, animals of all genotypes responded to thermal stimuli similarly. This suggests that estrogen signaling through ERβ is likely not part of the pathway of NTG-induced thermal sensitivity or that one copy of ERβ is sufficient for NTG-induced thermal sensitivity. Since ERβ is fully functional in CK1δ-T44A mice and CK1δ-T44A mice have wildtype thermal sensitivity at baseline, we can conclude that CK1δ-T44A does not modulate ERβ to affect thermal sensitivity in untreated animals.

No description available.

Polzerová, I: Use of kinase modulation in the Alzheimer's disease pathogenesis. Diploma thesis, Charles University in Prague, Faculty of Pharmacy in Hradec Králové, Department of Pharmaceutical Botany and Ecology, Hradec Králové 2016, 91 p. Data used in this Diploma Thesis have been taken from foreigner scientific literary sources. It provides the summary of the not yet explored natural compounds from marine organisms with kinase inhibitory activity. The first chapter Alzheimer's disease describes a characteristic of the disease, its etiopathogenesis, risk factors and currently available treatment. At the beginning of the second chapter are mentioned new perspective approaches to treatment of Alzheimer's disease. Most of this chapter deals with kinases as potential therapeutic targets in the treatment of Alzheimer's disease. In the chapter, physiologic and pathophysiologic functions of GSK-3β and CK-1δ are described in the organism, and also, other kinases are mentioned which are involved in the pathogenesis of the disease. Next part dedicates analytical methods suitable for testing activity and inhibition of kinases in vitro and in silico, also deals with summary of the synthetic kinase inhibitors and characterizes an their properties. In this chapter is also described main part of this work - the...

Inhibitors of topoisomerase II (topo II) are clinically effective in the management of hematological malignancies and solid tumors. The efficacy of anti-tumor drugs targeting topo II is often limited by resistance and studies with in vitro cell culture models have provided several insights on potential mechanisms. Multidrug transporters that are involved in the efflux and consequently reduced cytotoxicity of diverse anti-tumor agents suggest that they play an important role in resistance to clinically active drugs. However, in clinical trials, modulating the multidrug-resistant phenotype with agents that inhibit the efflux pump has not had an impact. Since reduced drug accumulation per se is insufficient to explain tumor cell resistance to topo II inhibitors several studies have focused on characterizing mechanisms that impact on DNA damage mediated by drugs that target the enzyme. Mammalian topo IIα and topo IIβ isozymes exhibit similar catalytic, but different biologic, activities. Whereas topo IIα is associated with cell division, topo IIβ is involved in differentiation. In addition to site specific mutations that can affect drug-induced topo II-mediated DNA damage, post-translation modification of topo II primarily by phosphorylation can potentially affect enzyme-mediated DNA damage and the downstream cytotoxic response of drugs targeting topo II. Signaling pathways that can affect phosphorylation and changes in intracellular calcium levels/calcium dependent signaling that can regulate site-specific phosphorylation of topoisomerase have an impact on downstream cytotoxic effects of topo II inhibitors. Overall, tumor cell resistance to inhibitors of topo II is a complex process that is orchestrated not only by cellular pharmacokinetics but more importantly by enzymatic alterations that govern the intrinsic drug sensitivity.

Rift Valley fever virus (RVFV) is a negative-sense RNA virus that is classified as an overlap select agent by the USDA and the HHS. It was first discovered in the Rift Valley of Kenya in the early 1930s. RVFV is an arbovirus that is transmitted by mosquitoes and infects ruminants and humans. RVFV in humans causes an acute self-limiting febrile illness but in a small percentage of cases, a severe version is noted by ocular disease, hepatitis, hemorrhagic fever, and death. In ruminants, the disease is similar with young livestock being the most susceptible. RVFV is also known to cause "abortion storms" where infected pregnant ruminants abort their fetuses with a near 100% fatality rate. Viruses are obligate intracellular parasites utilizing host-factors to replicate. This study identified three host-protein interactors of the viral Gn and L proteins that aid in viral replication. UBR4 was determined to be an interactor of Gn via immunoprecipitation followed by either LC/MS/MS or western blot analysis. Its inhibition via siRNA or CRISPR-Cas9 knockout showed a reduction of viral titers and viral RNA production. It was determined that UBR4 specifically affects viral RNA production and not entry or egress. Conversely, CK1α and PP1α were identified as binding partners of the L protein using similar methods. CK1α, a kinase, and PP1α, a phosphatase, were chosen for further verification due to data demonstrating the L protein is phosphorylated on at least one serine residue, in addition to PP1α already being shown to impact RVFV replication. Inhibition of CK1 and PP1 via small molecule inhibitors, D4476 and 1E7-03, respectively, showed a decrease in viral titers and RNA production. Strand-specific RT-qPCR demonstrates that CK1 and PP1 impact genomic replication. Upon treatment with D4476 a decrease in L protein phosphorylation was observed. Additionally, it has already been shown that treatment with 1E7-03 increases L protein phosphorylation. These data indicate that CK1 and PP1 modulate L protein phosphorylation, contributing to changes in RVFV replication. This study identifies three host-proteins that affect viral replication, which could be used as a foundation for host-based therapeutic and vaccine development. / Doctor of Philosophy / Rift Valley fever virus (RVFV) is a major biological threat due to its ability to infect both livestock and humans and be passed by mosquito bite. RVFV was first discovered in Africa in the early 1930s. To date, there is no approved therapeutic or vaccine. RVFV usually causes very mild disease but in a small percentage of cases, it progresses to include liver disease, vision loss, swelling of the brain, bleeding, and death. A virus itself is not alive; it needs a living host in order to replicate. To do this, it utilizes things naturally occurring inside the host. The purpose of this study is to identify host-factors that the virus uses in order to efficiently make more viruses. The first viral protein of interest is the glycoprotein, Gn, which is important for viral entry and assembly of the viral particles. It was determined that the host-protein UBR4 is an interactor of Gn and that the inhibition of UBR4 decreases the amount of infectious virus being produced. Similarly, the host-proteins, CK1α and PP1α, were found to be interactors of the viral L protein. The L protein is responsible for synthesizing the building blocks of the virus. It was determined that when CK1 and PP1 are inhibited, the L protein is less efficient at making these building blocks. Understanding the host-factors the virus utilizes is important to the basic understanding of how RVFV infects the host and the development of therapeutics to combat an outbreak.

The mutated forms of the Discs overgrown gene causes overproliferation of imaginal discs of Drosophila melanogaster. Somatic mutations in its human counterpart, casein kinase I epsilon, were strongly associated with human breast cancer. Using the advantage of a high conservancy between fly's dco and human casein kinase I epsilon genes we have chosen D. melanogaster as a model organism to provide a list of probable Dco interaction partners via tandem affinity purification and mass spectrometry analysis. However, these proteins need to be independently verified as true Dco interaction partners.

The study of DNA templated events is not complete without considering the chromatin environment. Histone modifications help to regulate gene expression, chromatin compaction and DNA replication. Because DNA damage repair must occur within the context of chromatin, many remodeling enzymes and histone modifications work in concert to enable access to the DNA and aid in restoration of chromatin after repair is complete. CK2 has recently been identified as a histone modifying enzyme. In this study we identify CK2 as a histone H3 tail kinase in vitro, identify the phospho-acceptor site in vitro, and characterize the modification in vivo in S. cerevisiae. We also characterize the DNA damage phenotype of a strain lacking a single catalytic subunit of CK2. We further characterize the CK2- dependent phosphorylation of serine 1 of histone H4 in vivo. We find that it is recruited directly to the site of a DSB and this recruitment requires the SIN3/RPD3 histone deacetylase complex. We also characterize the contribution of H4 serine 1 phosphorylation in chromatin compaction by using reconstituted nucleosomal arrays to study folding in the analytical ultracentrifuge.

La phosphorylation est une modification post-traductionnelle modulant l’activité, la conformation ou la localisation d’une protéine et régulant divers processus. Les kinases et phosphatases sont responsables de la dynamique de phosphorylation et agissent de manière coordonnée. L’activation anormale ou la dérégulation de kinases peuvent conduire au développement de cancers ou de désordres métaboliques. Les récepteurs tyrosine kinase (RTKs) sont souvent impliqués dans des maladies et la compréhension des mécanismes régissant leur régulation permet de déterminer les effets anticipés sur leurs substrats. Dans ce contexte, le but de cette thèse est d’identifier les évènements de phosphorylation intervenant dans la voie de l’insuline chez la drosophile impliquant un RTK : le récepteur de l’insuline (InR). La cascade de phosphorylation déclenchée suite à l’activation du récepteur est conservée chez le mammifère. Afin d’étudier le phosphoprotéome de cellules S2 de drosophile, nous avons utilisé une étape d’enrichissement de phosphopeptides sur dioxyde de titane suivie de leur séparation par chromatographie liquide (LC) et mobilité ionique (FAIMS). Les phosphopeptides sont analysés par spectrométrie de masse en tandem à haute résolution. Nous avons d’abord démontré les bénéfices de l’utilisation du FAIMS comparativement à une étude conventionnelle en rapportant une augmentation de 50 % dans le nombre de phosphopeptides identifiés avec FAIMS. Cette technique permet de séparer des phosphoisomères difficilement distinguables par LC et l’acquisition de spectres MS/MS distincts où la localisation précise du phosphate est déterminée. Nous avons appliqué cette approche pour l’étude des phosphoprotéomes de cellules S2 contrôles ou traitées à l’insuline et avons identifié 32 phosphopeptides (sur 2 660 quantifiés) pour lesquels la phosphorylation est modulée. Étonnamment, 50 % des cibles régulées possèdent un site consensus pour la kinase CK2. Une stratégie d’inhibition par RNAi a été implémentée afin d’investiguer le rôle de CK2 dans la voie de l’insuline. Nous avons identifié 6 phosphoprotéines (CG30085, su(var)205, scny, protein CDV3 homolog, D1 et mu2) positivement régulées suite à l’insuline et négativement modulées après le traitement par RNAi CK2. Par essai kinase in vitro, nous avons identifié 29 cibles directes de CK2 dont 15 corrélaient avec les résultats obtenus par RNAi. Nous avons démontré que la phosphorylation de su(var)205 (S15) était modulée par l’insuline en plus d’être une cible directe de CK2 suite à l’expérience RNAi et à l’essai kinase. L’analyse des données phosphoprotéomiques a mis en évidence des phosphopeptides isomériques dont certains étaient séparables par FAIMS. Nous avons déterminé leur fréquence lors d’études à grande échelle grâce à deux algorithmes. Le script basé sur les différences de temps de rétention entre isomères a identifié 64 phosphoisomères séparés par LC chez la souris et le rat (moins de 1 % des peptides identifiés). Chez la drosophile, 117 ont été répertoriés en combinaison avec une approche ciblée impliquant des listes d’inclusion. Le second algorithme basé sur la présence d’ions caractéristiques suite à la fragmentation de formes qui co-éluent a rapporté 23 paires isomériques. L’importance de pouvoir distinguer des phosphoisomères est capitale dans le but d’associer une fonction biologique à un site de phosphorylation précis qui doit être identifié avec confiance. / Phosphorylation is a reversible post-translational modification that modulates protein activity, and can impart conformational changes and affect translocation of their protein substrates. Kinases and phosphatases are responsible for the dynamic of changes in protein phosphorylation and act in a coordinated manner. Abnormal activation or misregulation of kinase activity can lead to the development of cancers and metabolic disorders. Tyrosine kinase receptor (RTK) associated signaling pathways are often implicated in numerous diseases and the further understanding of mechanisms affecting their regulation is necessary to determine their activity and effects anticipated on their substrates. In this context, the primary objective of this thesis is to study the phosphorylation events arising from the activation of the insulin receptor (InR) following stimulation of drosophila S2 cells with insulin. The phosphorylation cascade triggered after InR activation is conserved in mammals. In order to study the phosphoproteome of drosophila S2 cells, we enriched phosphopeptides on titanium dioxide (TiO2) stationary phase prior to their separation by liquid chromatography (LC) and ion mobility (FAIMS) mass spectrometry (MS). Phosphopeptides were then analysed by tandem MS at high resolution. We first compared the benefits of FAIMS to conventional LC-MS, and observed a 50% increase in the number of identified phosphopeptides when using ion mobility. FAIMS enables the separation of phosphoisomers that are typically unresolved by LC, enabling high confidence assignment of modification sites via distinct MS/MS spectra. This approach was used to profile phosphorylation changes taking place between control and insulin-treated drosophila cells and enabled the identification of 32 phosphopeptides (out of 2 660 quantified) showing differential regulation. Interestingly, 50% of the regulated targets have a CK2 consensus site. These preliminary experiments were followed-up by RNAi mediated inhibition of CK2 and revealed that 6 phosphoproteins (CG30085, su(var)205, scny, protein CDV3 homolog, D1 and mu2) were positively modulated after insulin stimulation and negatively regulated after CK2 RNAi treatment. Using in vitro kinase assay, we identified 29 direct CK2 targets, of which 15 were correlated with results from the CK2 RNAi experiment. We demonstrated specifically that the su(var)205 (S15) is regulated by insulin and is a direct CK2 target based on RNAi and kinase assays. Our phosphoproteomics data also highlighted the presence of isomeric phosphopeptides, several of which could be distinguished using FAIMS. We developed two algorithms to determine the occurrence of phosphoisomers in large scale studies. The first algorithm based on differences in retention times between isomers identified 64 candidates in mouse and rat phosphoproteome datasets corresponding to less than 1% of all identified phosphopeptides. We also identified 117 isomer candidates in drosophila using a targeted LC-MS/MS approach with inclusion lists. The second algorithm is based on the presence of characteristic fragment ions present in MS/MS spectra of co-eluting or partially resolved species and allowed the identification of 23 isomeric pairs. The ability to distinguish phosphoisomers in large-scale phosphoproteome datasets is of significance to correlate phosphorylation events taking place on specific residues with biological activities.

La protéine kinase caséine kinase 2 (CK2) est une sérine/thréonine kinase hautement pléiotrope dont la liste des substrats est supérieure à 500 protéines, lesquelles sont impliquées dans un large éventail de fonctions cellulaires. Les sous-unités catalytiques de CK2 (alpha et/ou alpha') sont constitutivement actives soit seules soit en combinaison avec les sous-unités régulatrices béta pour former une protéine hétérotétramérique (holoenzyme). Une troisième isoforme de la sous-unité catalytique, désignée CK2α'', a été découverte plus récemment et peu d'informations sont actuellement disponibles. L'activité hautement constitutive de CK2 est suspectée de contribuer au phénomène de néoplasie. Une stratégie de conception d'inhibiteurs tétracycliques ciblant le site ATP de la CK2 a permis l'élaboration de trois séries de composés comportant le motif indéno[1,2-b]indole. Un procédé multi-étapes de synthèse a permis de fonctionnaliser précisément le cycle D du noyau indéno[1,2-b]indole et de générer une première chimiothèque de molécules originales. Toutes les molécules finales ont été testées sur la protéine kinase humaine CK2 (Muenster) et certaines ont présentées des CI50 de l'ordre du submicromolaire. L'analyse des Relations Structure-Activité (SAR) et la construction d'un modèle 3D-QSAR (Duesseldorf) a contribué à affiner le choix des substituants introduits sur le châssis moléculaire développé. Les indéno[1,2-b]indoles fonctionnalisés les plus prometteurs ont été également testés sur d'autres cibles biologiques comme la phosphatase CDC25A (Metz) et la kinase DYRK1B (Saarbruecken). Des études de modélisation moléculaire (Duesseldorf) utilisant les données cristallographiques disponibles de l'enzyme ont permis d'analyser les interactions ligand-protéine. Les inhibiteurs les plus puissants in vitro ont été testés sur quatre lignées cellulaires normales afin d'établir leur profil cytotoxique (Centre de Recherche en Cancérologie de Lyon) / Synthesis and evaluation of indéno[1,2-b]indole derivatives as potential inhibitors of human protein kinase CK2 Protein kinase casein kinase 2 (CK2) is a serine/threonine kinase highly pleiotropic listed substrates it is greater than 500 proteins, which are involved in a wide range of cellular functions. The catalytic subunits of CK2 (α and/or α') are constitutively active either alone or in combination with the regulatory subunits to form a hetero- beta protein holoenzyme). A third isoform of the catalytic subunit, designated CK2 α', was discovered more recently and little information is currently available. The high constitutive activity of CK2 is suspected of contributing to the phenomenal of neoplasia. A design strategy tetracyclic inhibitors targeting the ATP site of CK2 resulted in the development of three series of compounds containing the motif indeno[1,2-b]indole. A multi-step synthesis process has specifically functionalize the D ring of the core indeno[1,2-b]indole and generate a first combinatorial library of original molecules. All final compounds were tested on human protein kinase CK2 (Muenster), and some have reported IC50 of the order of sub-micromolar. Analysis of Structure-Activity Relationships (SAR) and the construction of a 3D-QSAR model (Duesseldorf) helped to refine the choice of substituents introduced into the moleculair frame developed. The indeno[1,2-b]indole the most promising functionalized indoles were also tested on other biological targets such as phosphatase CDC25 A (Metz) and kinase DYRK1B (Saarbruecken). Of molecular modeling studies (Duesseldorf) using the crystallographic data of the enzyme were used to analyze protein-ligand interactions. The most potent in vitro inhibitor were tested on four normal cell lines to determine their cytotoxic profile (Cancer Research Center of Lyon)